Medications

What is Wegovy? A Complete Guide to the FDA-Approved Weight Loss Medication

If you've been researching weight loss medications, you've likely come across Wegovy. Since its FDA approval in 2021, this once-weekly injection has become one of the most talked-about treatments for chronic weight management. But what exactly is Wegovy, how does it work, and could it be right for you? Let's break down everything you need to know about this groundbreaking medication.

What is Wegovy?

Wegovy is the brand name for semaglutide when prescribed specifically for weight management. It's a prescription medication approved by the FDA for chronic weight management in adults with obesity or who are overweight with at least one weight-related health condition.

Manufactured by Novo Nordisk, Wegovy comes as a pre-filled injection pen that you use once weekly. The active ingredient, semaglutide, is also found in Ozempic (approved for type 2 diabetes) but Wegovy is formulated at higher doses specifically for weight loss.

How Does Wegovy Work?

Wegovy belongs to a class of medications called GLP-1 receptor agonists. GLP-1 stands for glucagon-like peptide-1, which is a hormone your body naturally produces in your intestines after eating.

Here's what Wegovy does in your body:

The result? You naturally eat less without the constant hunger that derails most diets. This isn't about willpower—it's about working with your body's natural signals rather than against them.

Who Is Wegovy For?

Wegovy is FDA-approved for adults with:

It's also approved for children ages 12 and older with obesity.

Wegovy is designed to be used alongside a reduced-calorie diet and increased physical activity—not as a replacement for healthy lifestyle habits.

Gender Considerations

Clinical trials for Wegovy included both women and men, though women have historically made up a larger portion of weight loss medication users. The medication works similarly across genders, though women may experience slightly different side effect profiles, particularly related to nausea. Some research suggests women may be more sensitive to GLP-1 medications initially, which is why the gradual dose escalation is especially important.

How Effective Is Wegovy?

The clinical trial results for Wegovy have been impressive. In the landmark STEP trials, participants lost an average of 15-17% of their body weight over 68 weeks when combining Wegovy with lifestyle changes.

To put that in perspective, someone weighing 240 pounds could expect to lose around 35-40 pounds on average. Some people lose more, some less—individual results vary based on factors like starting weight, adherence to the medication, diet, exercise, and metabolic differences.

Importantly, studies show that Wegovy helps people not just lose weight, but maintain that loss, which has traditionally been the hardest part of any weight loss journey.

Wegovy Dosing Schedule

Wegovy treatment starts low and increases gradually to help your body adjust and minimize side effects. The standard dosing schedule is:

You inject Wegovy yourself using a pre-filled pen, similar to how people with diabetes administer insulin. The injection goes into fatty tissue under your skin—typically in your abdomen, thigh, or upper arm. Most people find it quick and relatively painless after the first few times.

Common Side Effects

Like all medications, Wegovy can cause side effects. The most common are gastrointestinal and usually improve as your body adjusts:

These side effects are typically mild to moderate and tend to decrease over time, especially with the gradual dose increase. Eating smaller meals, avoiding high-fat foods, and staying hydrated can help manage these symptoms.

Serious side effects are rare but can include pancreatitis, gallbladder problems, and thyroid tumors (seen in animal studies). Wegovy is not recommended for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Wegovy vs. Other Weight Loss Medications

You might wonder how Wegovy compares to other options. Ozempic contains the same active ingredient (semaglutide) but is FDA-approved for type 2 diabetes, not weight loss, though it's sometimes prescribed off-label for weight management.

Other GLP-1 medications include Mounjaro and Zepbound (tirzepatide), which work on both GLP-1 and GIP receptors and may produce even greater weight loss in some people.

Compounded semaglutide offers the same active ingredient as Wegovy at a more accessible price point, made by specialized pharmacies when brand-name medications are in shortage or cost-prohibitive.

Cost and Accessibility

Brand-name Wegovy typically costs over $1,300 per month without insurance. Some insurance plans cover it, but coverage varies widely and often requires prior authorization demonstrating medical necessity.

The high cost has led many people to explore compounded semaglutide options, which offer the same active ingredient at a fraction of the price, making this effective treatment accessible to more people who could benefit.

From the Ozari Care Team

Starting any weight loss medication works best when combined with sustainable lifestyle changes. We recommend focusing on protein-rich foods and staying well-hydrated to minimize GI side effects while maximizing results. Remember, these medications are tools that work with your commitment to healthier habits—not magic solutions that work in isolation.

Ready to Start Your Weight Loss Journey?

At Ozari Health we offer compounded Semaglutide and Tirzepatide as low as $99/month prescribed by licensed physicians and shipped to your door. Learn more at ozarihealth.com.

Medically Reviewed — Ozari Clinical Content Team (OCCT). Health writers and wellness professionals specializing in GLP-1 therapy, metabolic health, and weight loss medicine. Content reviewed in accordance with Ozari's Editorial Standards. Last reviewed: April 25, 2026.

This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.

Last reviewed: April 25, 2026